1. Recent Advances in Dipeptidyl-Peptidase-4 Inhibition Therapy: Lessons from the Bench and Clinical Trials
   Jixin Zhong et al, 2015, Journal of Diabetes Research CrossRef
2. The Dipeptidyl Peptidase-4 Inhibitor Teneligliptin Attenuates Hepatic Lipogenesis via AMPK Activation in Non-Alcoholic Fatty Liver Disease Model Mice
   Takayasu Ideta et al, 2015, IJMS CrossRef
3. Extrapancreatic Effect of Glucagon like Peptide-1
   In-Kyung Jeong, 2015, Korean J Med CrossRef
4. Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors
   Vasiliki Bistola et al, 2018, Heart Fail Rev CrossRef
5. Anti-Diabetic Medications for the Pharmacologic Management of NAFLD
   Rosann Cholankeril et al, 2018, Diseases CrossRef
6. Linagliptin Attenuates the Cardiac Dysfunction Associated With Experimental Sepsis in Mice With Pre-existing Type 2 Diabetes by Inhibiting NF-κB
   Sura Al Zoubi et al, 2018, Front. Immunol. CrossRef
7. Physiology and Pharmacology of DPP-4 in Glucose Homeostasis and the Treatment of Type 2 Diabetes
   Carolyn F. Deacon, 2019, Front. Endocrinol. CrossRef
8. Resveratrol Reduces Glucolipid Metabolic Dysfunction and Learning and Memory Impairment in a NAFLD Rat Model: Involvement in Regulating the Imbalance of Nesfatin-1 Abundance and Copine 6 Expression
   Xing-Xing Chen et al, 2019, Front. Endocrinol. CrossRef
9. Dipeptidyl peptidase-4 inhibition prevents nonalcoholic steatohepatitis–associated liver fibrosis and tumor development in mice independently of its anti-diabetic effects
   Mitsuhiro Kawakubo et al, 2020, Sci Rep CrossRef
10. Gut-Pancreas-Liver Axis as a Target for Treatment of NAFLD/NASH
    Gianluca Svegliati-Baroni et al, 2020, IJMS CrossRef
11. Circulating dipeptidyl peptidase-4 is independently associated with the presence and severity of NAFLD/NASH in individuals with and without obesity and metabolic disease
    Ilaria Barchetta et al, 2020, J Endocrinol Invest CrossRef
12. Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
    Waihong Chung et al, 2020, WJH CrossRef
13. Dipeptidyl peptidase-4 inhibitor protects against non-alcoholic steatohepatitis in mice by targeting TRAIL receptor-mediated lipoapoptosis via modulating hepatic dipeptidyl peptidase-4 expression
    Minyoung Lee et al, 2020, Sci Rep CrossRef
14. DNA Methylation in Nonalcoholic Fatty Liver Disease
    Jeongeun Hyun et al, 2020, IJMS CrossRef
15. Emerging Roles of Dipeptidyl Peptidase-4 Inhibitors in Delaying the Progression of Type 1 Diabetes Mellitus
    Jaquellyne Gurgel Penaforte-Saboia et al, 2021, DMSO CrossRef
16. The rs12617336 and rs17574 Dipeptidyl Peptidase-4 Polymorphisms Are Associated With Hypoalphalipoproteinemia and Dipeptidyl Peptidase-4 Serum Levels: A Case-Control Study of the Genetics of Atherosclerotic Disease (GEA) Cohort
    Gilberto Vargas-Alarcón et al, 2021, Front. Genet. CrossRef
17. Association between nonalcoholic fatty liver disease and incident diabetes mellitus among Japanese: a retrospective cohort study using propensity score matching
    Xiaodan Zheng et al, 2021, Lipids Health Dis CrossRef
18. Mapping Salivary Proteases in Sjögren’s Syndrome Patients Reveals Overexpression of Dipeptidyl Peptidase-4/CD26
    Laís Garreto et al, 2021, Front. Immunol. CrossRef
19. Multifactorial Basis and Therapeutic Strategies in Metabolism-Related Diseases
    João V. S. Guerra et al, 2021, Nutrients CrossRef
20. Gardenoside Hinders Caspase-1-Mediated Hepatocyte Pyroptosis Through the CTCF/DPP4 Signaling Pathway
    Tian Shen et al, 2021, Front. Physiol. CrossRef
21. Maternal Nutrient Restriction Disrupts Gene Expression and Metabolites Associated with Urea Cycle, Steroid Synthesis, Glucose Homeostasis, and Glucuronidation in Fetal Calf Liver
    Susumu Muroya et al, 2022, Metabolites CrossRef
22. Potential Effect of DPP-4 Inhibitors Towards Hepatic Diseases and Associated Glucose Intolerance
    Ashwani Sharma et al, 2022, DMSO CrossRef
23. Association of the rs17574 DPP4 Polymorphism with Premature Coronary Artery Disease in Diabetic Patients: Results from the Cohort of the GEA Mexican Study
    Gilberto Vargas-Alarcón et al, 2022, Diagnostics CrossRef
24. Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
    Alba Sebastián-Martín et al, 2022, Biomedicines CrossRef
25. Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction
    Giang Nguyen et al, 2022, Endocrinol Metab CrossRef
26. DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
    Ji Cheol Bae, 2022, Endocrinol Metab CrossRef
27. Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, modulates glucose production, and when absent influences NAFLD progression
    Natasha A. Trzaskalski et al, 2023 CrossRef
28. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review
    Maria Zachou et al, 2023, Eur J Clin Pharmacol CrossRef
29. DPP4 in Cardiometabolic Disease
    Jixin Zhong et al, 2015, Circulation Research CrossRef
30. Fabrication of a Near-Infrared-Emissive Probe for Detecting Dipeptidyl Peptidase 4 in the Liver of Diabetic Mice and Clinical Serum
    Minhui Liu et al, 2024, Anal. Chem. CrossRef
31. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease
    Ye Liu, 2014, WJG CrossRef
32. Higher Serum Dipeptidyl Peptidase-4 Activity in Newly Diagnosed Young-Onset Type 2 Diabetes Mellitus
    Tahseen Mahmood et al, 2024 CrossRef